GLP-1 plays a crucial role in glucose metabolism by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite and food intake
Understanding these fundamental differences in mechanism, evidence base, and regulatory status is essential when considering any combination therapy
In early 2023, semaglutide also gained FDA approval to treat obesity in pediatric patients aged 12 years and older [6, 7]
Similarly, Semaglutide, administered once weekly at dosages ranging from 0.65 to 0.98 mg, demonstrated significantly better efficacy than Liraglutide, which ranges from 0.78 to 3 mg daily, in reducing HbA1c levels
[4] Ozempic is often prescribed off-label for the treatment of obesity in overweight individuals
Oral semaglutide tablets should only be kept at room temperature and should not be put in the fridge